Biotechnology is one of the most dynamic fields of modern innovation, spanning from health and agriculture to the food and environmental industries. In this context, biotechnology patents play a fundamental role in protecting inventions and fostering investment in research. This article explores what biotechnology patents are, why they are crucial for innovation, the main legal challenges associated with obtaining them in Europe and Latin America, the regulatory differences between both regions, the most relevant cases and precedents, the business opportunities derived from a sound protection strategy, and the role of specialized firms like ISERN Patentes y Marcas in supporting entrepreneurs and researchers in this field.
What biotechnology patents are and why they drive innovation
A patent is an exclusive right granted by a State that allows the holder to exploit an invention for a limited period, generally twenty years. In the biotechnology sector, patents can protect new products or processes derived from biology, such as medicines, vaccines, genetically modified microorganisms, genetic sequences, or diagnostic methods. These patents grant a temporary monopoly over the invention, preventing third parties from using it without authorization. In exchange, the inventor discloses the technical details, enriching scientific knowledge and promoting new advances.
Biotechnology patents are an essential engine for innovation. Developing a new biotechnological product—such as a drug or an improved plant variety—requires years of research and high investment. Patent protection guarantees the possibility of recovering that investment through commercial exclusivity, which incentivizes companies and investors to commit to innovative projects. In Europe, patent-intensive sectors, including biosciences, represent a significant portion of employment and GDP. In Latin America, strengthening intellectual property protection is considered key to boosting high-tech and knowledge-based industries.
Ultimately, biotechnological patents allow scientific creativity to be transformed into market opportunities. They favor the return on investment, encourage technology transfer, and promote the dissemination of technical knowledge for the benefit of society once the patent expires.
Legal challenges in the patentability of biotechnological inventions
Patenting in biotechnology entails significant legal challenges. Inventions based on living organisms and biological material raise unique dilemmas regarding patentability, technical criteria, and ethical considerations.
One of the main challenges is determining what can be considered an invention in biology. Many countries exclude from patentability discoveries of things that exist in nature. For example, biological material as it is found in nature is not considered an invention, but rather a discovery. This affects cases such as the isolation of genes or natural proteins: if the applicant’s contribution is simply finding and isolating an existing genetic sequence, it may not meet the invention requirement. To resolve this boundary, some systems require significant human intervention that converts the discovery into a patentable technical application.
Living organisms in biotechnology patents
Another important challenge is the patentability of living organisms, such as plants, animals, and microorganisms. In Europe, the European Patent Convention excludes plant varieties and animal breeds from patentability, although it allows for the patenting of microorganisms and genetically modified organisms. Directive 98/44/EC confirmed this possibility and also allowed for the patenting of plants or animals as long as the technical invention is not limited to a specific variety. However, in Latin America, many countries are more restrictive. The legislation of the Andean Community prohibits patenting plants, animals, and their parts, which has led to the rejection of applications for hybrid or transgenic seeds. In Peru, for example, an isolated gene is not considered a patentable invention, and cases such as those involving Monsanto demonstrate the strict application of these rules.
The patentability of genes and genetic material also generates debate. In Europe, it is permitted to patent an element isolated from the human body, such as a gene, if it is obtained through a technical process and has a specific industrial application. In contrast, many Latin American countries reject so-called “gene patents,” considering that natural genetic sequences should not be subject to monopoly. Others, such as Argentina, establish stricter requirements for disclosure and experimental support to accept these types of applications.
Biotechnology patents in diagnostic and therapeutic methods
There are also limitations related to diagnostic and therapeutic methods. In Europe, surgical or diagnostic treatment methods applied directly to the human or animal body are not patentable. Only kits or in vitro procedures used in a laboratory can be patented. Latin America generally maintains a similar position, although some countries allow for the patenting of diagnostic methods as long as they are performed outside the human body. This nuance forces companies to structure their applications with technical precision to avoid legal exclusions.
Ethical issues
Ethical issues constitute another fundamental limit. Biotechnology involves sensitive aspects of life; therefore, European and Latin American laws establish prohibitions for inventions contrary to morality, public order, or human dignity. In Europe, Directive 98/44/EC prevents patenting human cloning procedures, germline genetic modification, or the use of embryos for industrial purposes. In Latin America, many legislations include similar moral clauses, reinforced by the interest in avoiding biopiracy. Countries such as Peru, Brazil, or Costa Rica require that inventions based on biological resources or traditional knowledge provide evidence of access permits and benefit-sharing, adding a specific regulatory layer.
In short, patenting in biotechnology requires navigating a complex regulatory framework, where the differences between discovery and invention, ethical restrictions, and legislative diversity can be decisive for the success or failure of an application.
Regulatory differences between Europe and Latin America in biotechnology patents
Europe and Latin America present significant differences in how they regulate the protection of biotechnological inventions. In Europe, there is a more harmonized structure thanks to the European Patent Convention and Directive 98/44/EC, which establish uniform patentability criteria. Furthermore, the European Patent Office allows for protection to be obtained in several countries through a single procedure. In contrast, Latin America lacks a unified regional system. Each country has its own industrial property law, with notable differences in criteria and exceptions. Andean countries share common rules through Decision 486, but other nations such as Brazil, Mexico, Argentina, or Chile apply different regulations. This forces companies to plan a country-by-country strategy, as the same invention may be patentable in some places and not in others.
Europe also typically applies criteria more favorable to the protection of biotechnologies, allowing for the patentability of genes, antibodies, or modified cells, provided that the requirements of novelty and industrial application are met. In Latin America, on the other hand, a more restrictive view prevails that excludes living organisms, natural genes, or new pharmaceutical forms from protection, prioritizing access to medicines and environmental protection.
To this is added a difference in institutional capacity. European offices have specialized examiners and more agile procedures. In Latin America, some countries face significant delays and technical limitations in the examination of biotechnological applications. This generates legal uncertainty and can discourage investment in research. Likewise, in Latin America, bioethics and the defense of biodiversity significantly influence legislation, with an emphasis on preventing biopiracy and protecting natural resources.
Relevant cases and precedents
Over the last few decades, several emblematic cases have marked the evolution of biotechnological patents. Among them stands out the Chakrabarty case (United States, 1980), which recognized for the first time the possibility of patenting a modified living organism. Although it was a US case, it decisively influenced the global acceptance of biotechnology patents.
Another important precedent was the “Harvard OncoMouse,” the first transgenic animal patented in Europe, which opened the debate on the ethical limits of these inventions. In Latin America, the controversy over Monsanto’s transgenic soy in Argentina highlighted international differences: the company failed to patent in Argentina, but did so in Europe, generating commercial conflicts between both regions. Also in Peru, the rejection of transgenic seed patents reaffirmed the Andean Community’s strict stance toward living matter.
In Europe, the case Brüstle vs. Greenpeace (2011) marked a turning point by establishing that inventions involving the destruction of human embryos cannot be patented. The decision of the Court of Justice of the European Union set clear ethical limits in biotechnology, promoting alternatives such as adult or induced stem cells. In Latin America, on the other hand, the debate has focused more on avoiding “evergreening” practices or the undue extension of pharmaceutical patents, as shown by Argentine patentability guides or recent reforms in Brazil.
These cases reflect the balance that industrial property systems must maintain between promoting innovation and guaranteeing respect for ethical and social principles. They also demonstrate that regional differences can generate commercial and regulatory tensions in an increasingly global sector.
Business opportunities in patent-protected biotechnology
An adequate protection strategy not only avoids legal risks but also opens up significant business opportunities. Patents offer market exclusivity, allowing for the recovery of investment in research and development. For biotechnology startups, having a solid patent can be key to attracting funding or establishing themselves in the market without direct competition.
Additionally, patents allow for the generation of income through licensing or the sale of rights. Many universities and research centers patent their findings to transfer them to companies with industrial capacity. This technology transfer model drives the creation of new spin-off companies and favors public-private collaboration. It also strengthens the competitive position of companies, which can negotiate alliances or joint development agreements from a solid legal basis.
In financial terms, patents increase corporate value and facilitate the attraction of investment. For capital funds and large pharmaceutical companies, a patent portfolio is synonymous with security and growth potential. In this way, patents become strategic assets that not only protect innovation but also drive the economic development of an entire sector.
The role of ISERN in biotechnology patents
The legal landscape of biotechnology is complex and requires specialized advice. Firms like ISERN Patentes y Marcas play a key role in accompanying researchers, entrepreneurs, and companies at every stage of the protection process.
At ISERN, we have extensive international experience in industrial property and more than a century of history. Our team of experts offers personalized strategies that help determine the best way to protect an invention, adapting applications to the regulations of each country and avoiding legal exclusions. We also advise on the technical drafting of patents, administrative management, defense against oppositions, and maintenance of rights—something essential for biotechnology patents.
We incorporate technological intelligence services, international expansion reports, and advanced digital tools that facilitate strategic decision-making. These capabilities allow biotechnology companies to identify trends, monitor competition, and detect opportunities in emerging markets. Finally, we facilitate technology transfer agreements and valuation of intellectual property assets, helping to transform innovation into real growth.
In short, having a specialized partner like ISERN Patentes y Marcas allows scientific research and biotechnological entrepreneurship to translate into sustainable competitive advantages, boosting innovation and economic development. If you need help with biotechnology patents, talk to us. Our experts will give you the best advice.